Physician profile
Stacy L Utton
NPI 1912351404
$7,607.43
in general payments reported to CMS, 2019-2025
30 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $816 · 2022: $1,440 · 2023: $1,990 · 2024: $1,905 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,314 · Education: $36.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,314.43 |
| Education | $36.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,297.58 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,029.25 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $856.52 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $521.16 | 2023-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $469.17 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $428.95 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $284.64 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $265.18 | 2021-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $242.73 | 2021-2025 | Ocaliva |
| Gilead Sciences, INC. | $206.04 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $129.15 | 2021-2023 | |
| Pfizer INC. | $127.65 | 2022-2025 | |
| Celgene Corporation | $120.07 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $104.27 | 2021-2023 | Dificid, Delstrigo |
| Janssen Scientific Affairs, LLC | $101.66 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $89.32 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $55.18 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $33.45 | 2024-2025 | Iqirvo |
| Tersera Therapeutics LLC | $26.99 | 2022 | |
| Qol Medical, LLC | $25.98 | 2025 | Sucraid |
| Madrigal Pharmaceuticals | $23.68 | 2025 | Rezdiffra |
| Enterra Medical, INC. | $23.38 | 2025 | |
| Organon LLC | $22.52 | 2023 | Hadlima |
| Biocon Biologics INC | $21.77 | 2025 | Yesintek |
| Ferring Pharmaceuticals INC. | $21.61 | 2022 | |
| Lilly USA, LLC | $19.20 | 2025 | Omvoh |
| Daiichi Sankyo INC. | $18.85 | 2021 | |
| Evoke Pharma, INC. | $14.44 | 2024 | |
| Braintree Laboratories, INC. | $13.73 | 2022 | |
| Intra-Sana Laboratories | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Utton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.